Integrating MCDA and economic evaluation into a rule-based framework for hospital-level health technology assessment
Global and Regional Health Technology Assessment · 27.07.2026 · 13 (1) · 201-210
DOI: 10.33393/grhta.2026.3811 ↗Kurz gefasst
Fachartikel in der Zeitschrift Global and Regional Health Technology Assessment, online erschienen am 27.07.2026. Verfasst von Gianpaolo Franzoso und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Oncology and Services, Pharmacy Unit, Veneto Institute of Oncology IOV IRCCS, Padua - Italy. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Health Technology Assessment (HTA) supports evidence-based decision-making, but integrating economic evaluation within Multi-Criteria Decision Analysis (MCDA) remains challenging in hospital-level HTA.This study developed and preliminarily applied an integrated decision-support framework combining MCDA, economic evaluation, and contextualized evidence assessment to support adoption recommendations.
Methods
A pragmatic digital framework integrated MCDA with Budget Impact Analysis (BIA) and Cost-Consequence Analysis (CCA) within a rule-based decision matrix. The economic module estimated cost per patient, incremental cost, budget impact, cost-consequence outputs, and, when appropriate, a supportive soft ICER. Evidence was assessed through structured critical appraisal, Summary of Findings tables, and outcome relevance, using a GRADE-informed approach mapped onto the predefined 0-1-3-5-7-9 MCDA evidence scale. Operational robustness was assessed through Failure Mode and Effects Analysis (FMEA) and self-audit controls.
Results
In a case study comparing disposable and reusable continence care systems, the disposable option showed a lower MCDA score than the current standard (2.60 vs 4.80; ΔMCDA = -2.20) and a higher cost per patient (€1.00 vs €0.65; incremental cost €0.35). Although the 3-year budget impact was €2,634 and remained within the institutional affordability threshold, the technology was classified as dominated because it generated lower value at a higher cost. The final recommendation was not favorable for routine adoption.
Conclusion
The framework supports transparent integration of MCDA and economic evaluation in hospital-level HTA and helps distinguish affordability from overall value. The case study suggests that technologies should not be adopted solely because their budget impact is acceptable when the value-risk profile is unfavorable. Further validation across technologies and settings is required.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Translational Oncology and Services, Pharmacy Unit, Veneto Institute of Oncology IOV IRCCS, Padua - Italy.
- Postgraduate School of Pharmacology and Clinical Toxicology, University of Brescia, Brescia - Italy.
- General Directorate, Veneto Institute of Oncology IOV IRCCS, Padua - Italy.
ORCID-Profile: Gianpaolo Franzoso, Novella Piazzetta, Flavio Cazzador, Giorgia Zorzetto, Marina Coppola
Zitieren
APA
Franzoso, G., Piazzetta, N., Cazzador, F., Zorzetto, G., Simionato, P., & Coppola, M. (2026). Integrating MCDA and economic evaluation into a rule-based framework for hospital-level health technology assessment. Global and Regional Health Technology Assessment, 13(1), 201-210. https://doi.org/10.33393/grhta.2026.3811
Vancouver
Franzoso G, Piazzetta N, Cazzador F, Zorzetto G, Simionato P, Coppola M. Integrating MCDA and economic evaluation into a rule-based framework for hospital-level health technology assessment. Global and Regional Health Technology Assessment. 2026;13(1):201-210. doi:10.33393/grhta.2026.3811
BibTeX
@article{Franzoso2026,
author = {Franzoso, Gianpaolo and Piazzetta, Novella and Cazzador, Flavio and Zorzetto, Giorgia and Simionato, Patrizia and Coppola, Marina},
title = {Integrating MCDA and economic evaluation into a rule-based framework for hospital-level health technology assessment},
journal = {Global and Regional Health Technology Assessment},
year = {2026},
volume = {13},
number = {1},
pages = {201--210},
doi = {10.33393/grhta.2026.3811}
}
EUVIMED